Hemo Organic Ltd
₹ 10.2
-4.96%
03 Jul
- close price
About
Incorporated in 1992, Hemo Organic Ltd manufactures Ayurvedik or Unani pharmaceutical preparation[1]
Key Points
- Market Cap ₹ 3.53 Cr.
- Current Price ₹ 10.2
- High / Low ₹ 15.2 / 8.05
- Stock P/E 22.0
- Book Value ₹ -0.43
- Dividend Yield 0.00 %
- ROCE 2.65 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 16.8%
- Company has high debtors of 382 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.71 | 0.16 | 0.11 | 0.60 | 0.09 | 0.05 | 0.27 | 0.01 | 0.01 | 0.00 | 0.01 | 2.41 | |
| 0.79 | 0.22 | 0.16 | 0.68 | 0.24 | 0.17 | 0.29 | 0.06 | 0.07 | 0.05 | 0.25 | 2.45 | |
| Operating Profit | -0.08 | -0.06 | -0.05 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.24 | -0.04 |
| OPM % | -11.27% | -37.50% | -45.45% | -13.33% | -166.67% | -240.00% | -7.41% | -500.00% | -600.00% | -2,400.00% | -1.66% | |
| 0.23 | 0.02 | -0.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | |
| Interest | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Depreciation | 0.09 | 0.07 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.04 | -0.11 | -0.82 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.26 | 0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -466.67% |
| 0.04 | -0.11 | -0.82 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.26 | 0.16 | |
| EPS in Rs | 0.12 | -0.32 | -2.37 | -0.23 | -0.43 | -0.35 | -0.06 | -0.14 | -0.17 | -0.14 | -0.75 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 55% |
| 3 Years: | 522% |
| TTM: | 24000% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 58% |
| 3 Years: | 67% |
| TTM: | 162% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | % |
| 3 Years: | -38% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.40 | 3.40 | 3.40 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 |
| Reserves | -1.92 | -2.16 | -2.98 | -3.06 | -3.21 | -3.33 | -3.35 | -3.40 | -3.46 | -3.52 | -3.78 | -3.62 |
| 0.05 | 0.05 | 0.00 | 0.00 | 0.08 | 0.08 | 0.00 | 0.04 | 0.04 | 0.04 | 1.24 | 1.48 | |
| 0.14 | 0.08 | 0.11 | 0.72 | 0.66 | 0.73 | 0.13 | 0.12 | 0.19 | 0.35 | 0.14 | 3.65 | |
| Total Liabilities | 1.67 | 1.37 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 4.98 |
| 1.12 | 0.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.55 | 0.45 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 4.98 | |
| Total Assets | 1.67 | 1.37 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 4.98 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.06 | -0.78 | -0.15 | -0.12 | -0.04 | 0.01 | -0.01 | 0.00 | 0.11 | -1.19 | -0.36 | |
| 0.02 | 0.00 | 0.70 | 0.02 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -0.17 | 0.00 | 0.08 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | 0.24 | |
| Net Cash Flow | -0.09 | 0.07 | 0.00 | 0.01 | -0.06 | -0.01 | 0.01 | -0.01 | 0.00 | 0.11 | 0.01 | -0.12 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 159.37 | 342.19 | 0.00 | 438.00 | 2,920.00 | 5,402.00 | 94.63 | 2,555.00 | 2,190.00 | 2,920.00 | 381.66 | |
| Inventory Days | 0.00 | 0.00 | 0.00 | 20.66 | 91.25 | 0.00 | 0.00 | 0.00 | 730.00 | 235.59 | ||
| Days Payable | 392.55 | 3,011.25 | 4,015.00 | 602.25 | ||||||||
| Cash Conversion Cycle | 159.37 | 342.19 | 0.00 | 66.11 | 0.00 | 5,402.00 | 94.63 | 2,555.00 | -1,095.00 | 2,920.00 | 15.00 | |
| Working Capital Days | 97.68 | 228.12 | 232.27 | 146.00 | 689.44 | 438.00 | -67.59 | -1,825.00 | -4,015.00 | 23,725.00 | 156.00 | |
| ROCE % | -10.56% | -7.80% | -12.87% | -19.28% | -40.00% | -42.86% | -11.76% | -43.48% | -75.00% | -250.00% | -52.17% | 2.65% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Jun - Appointed new independent director and company secretary; reconstituted key committees effective 27 June 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E., Friday, 27Th June, 2025.
27 Jun - Appointed new Independent Director and Company Secretary; reconstituted key board committees on June 27, 2025.
-
Closure of Trading Window
24 Jun - Trading window closed from July 1, 2025 till 48 hours post Q1 June 30, 2025 results announcement.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
24 Jun - Company Secretary Garima Jain resigned on 23 June 2025 to pursue new career opportunities.
-
Integrated Filing (Financial)
23 May - Audited FY25 results with qualified opinion due to unconfirmed trade balances; net profit Rs16.39L; going concern doubts noted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1][2]
Company used to manufacture 2,6 Di Chloro Aniline which is used as an intermediate in bulk drugs and Para Chloro Meta Cresol which is used in the leather industry in its Kheda plant with an installed capacity of 110 MTPA for 2,6 Dichloro aniline and 220 MTPA for para Chloro Meta Cresol. At present, company deals in ayurvedic or unani preparations